Does BPC-157 Cause Flushing? What FDA Has Recorded

Does BPC-157 cause histamine flushing?

FDA's July 2026 review does not describe flushing as an effect of BPC-157. Its search of the adverse-event database through December 4, 2025 found three reports, all for injectable BPC-157 [1]:

• injection-site redness and swelling that lasted 9 days, in a patient who also used compounded thymosin;
• shortness of breath that led to an emergency room visit, with no other detail given;
• widespread skin and gum darkening that returned when the person was exposed again to a BPC-157 plus TB-500 'research' product.

FDA said it cannot tell whether BPC-157 caused any of these events [1]. Two are local or skin changes and one is a breathing event, and FDA recorded them as separate reports. Its account does not give enough detail to assign any of them a flushing severity grade.

What the human evidence shows

The human studies FDA reviewed used rectal enemas, injections into the knee, injections around the bladder wall and two intravenous infusions [1]. In those studies no serious adverse events were reported, but the studies were short and small and gave limited safety information. In the healthy-volunteer enema studies, which exist as meeting abstracts, the most frequent events were headache and flatulence [1]. FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, as a nasal spray or on the skin, even though websites sell it in injectable, capsule, oral-spray and nasal-spray forms [1].

A 2026 systematic review of human BPC-157 evidence in orthopaedic and regenerative use included three studies covering 30 patients. All were of poor methodological quality and the certainty of evidence was rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [4]. FDA identified five small human studies in total [1].

What FDA says about how BPC-157 works

FDA states that BPC-157's molecular targets have not been identified, that its mechanisms 'remain poorly understood', and that dose-response relationships for the protective effects reported in animals were not established. Those reported effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies, not human trials [1].

FDA's page on bulk substances that may raise safety risks when compounded, which now lists BPC-157 in its 'nominated but withdrawn' table, still carries FDA's concerns. They include possible immunogenicity for certain routes of administration and peptide-related impurities. FDA also said it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [3].

Reporting a reaction

MedWatch is FDA's safety reporting program for health professionals, patients and consumers, and suspected reactions can be reported through it [2].